Symbols / HELP Stock $5.77 +17.04% Cybin D/B/A Helus Pharma

Healthcare • Biotechnology • Canada • NGM
HELP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Stock Fundamentals
Scroll to Statements
Market Cap 287.89M Enterprise Value 758.26M Income -123.22M Sales — Book/sh 0.05 Cash/sh 0.00
Dividend Yield — Payout 0.00% Employees 50 IPO — P/E — Forward P/E -1.79
PEG — P/S — P/B 107.35 P/C — EV/EBITDA -6.36 EV/Sales —
Quick Ratio 12.36 Current Ratio 13.78 Debt/Eq — LT Debt/Eq — EPS (ttm) -4.30 EPS next Y -3.22
EPS Growth — Revenue Growth — Earnings 2026-02-13 ROA -31.95% ROE -55.89% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 49.89M Shs Float 90.79M Short Float —
Short Ratio 2.79 Short Interest — 52W High 9.83 52W Low 4.29 Beta 1.04 Avg Volume 1.05M
Volume 2.50M Target Price $43.97 Recom Strong_buy Prev Close $4.93 Price $5.77 Change 17.04%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$43.97
Mean price target
2. Current target
$5.77
Latest analyst target
3. DCF / Fair value
$-25.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.77
Low
$8.08
High
$94.64
Mean
$43.97

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-13 init TD Cowen — → Buy $8
2026-03-02 main HC Wainwright & Co. Buy → Buy $95
2025-12-03 main Guggenheim Buy → Buy $48
2025-11-20 main Canaccord Genuity Buy → Buy $45
2025-11-14 main HC Wainwright & Co. Buy → Buy $55
News
RSS: Latest HELP news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-24 Lewis-Hall (Freda C) Director of Issuer — 0 — —
2026-02-20 Bartlone (Aaron Frank) Senior Officer of Issuer — 5,416 — —
2026-02-20 Cavers (Gregory Joseph) Senior Officer of Issuer — 4,075 — —
2026-02-20 Fahel (Gabriel) Senior Officer of Issuer — 8,333 — —
2026-02-20 Tziras (George) Senior Officer of Issuer — 1,104 — —
2026-02-10 Cola (Michael F) Senior Officer of Issuer — 0 — —
2026-01-08 Bartlone (Aaron Frank) Senior Officer of Issuer — 3,140 $7.15 $22,441
2026-01-08 Tziras (George) Senior Officer of Issuer — 989 $7.15 $7,068
2026-01-06 Bartlone (Aaron Frank) Senior Officer of Issuer — 8,333 — —
2026-01-06 Cavers (Gregory Joseph) Senior Officer of Issuer — 8,333 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Cost Of Revenue
—
—
—
0.00
Reconciled Cost Of Revenue
—
—
—
0.00
Gross Profit
—
—
—
0.00
Operating Expense
143.15
+81.58%
78.84
+53.03%
51.52
-19.30%
63.84
Research And Development
54.91
+69.67%
32.36
+26.95%
25.49
+44.95%
17.59
Selling General And Administration
88.24
+89.86%
46.47
+78.56%
26.03
-43.73%
46.25
Selling And Marketing Expense
3.29
+17.12%
2.81
+218.46%
0.88
-39.90%
1.47
General And Administrative Expense
84.95
+168.93%
31.59
+25.62%
25.15
-43.85%
44.79
Salaries And Wages
56.02
+153.07%
22.13
+101.99%
10.96
-57.02%
25.50
Other Gand A
28.94
+90.27%
15.21
+7.19%
14.19
-26.44%
19.29
Total Expenses
143.15
+81.58%
78.84
+53.03%
51.52
-19.30%
63.84
Operating Income
-143.15
-81.58%
-78.84
-53.03%
-51.52
+19.30%
-63.84
EBITDA
-142.67
-81.95%
-78.41
-52.95%
-51.27
-0.53%
-51.00
Normalized EBITDA
-164.39
-109.29%
-78.55
-43.62%
-54.69
-14.50%
-47.77
Reconciled Depreciation
0.47
+12.03%
0.42
+68.92%
0.25
+49.40%
0.17
EBIT
-143.15
-81.58%
-78.84
-53.03%
-51.52
-0.75%
-51.13
Total Unusual Items
21.72
+15754.74%
0.14
-96.00%
3.42
+184.90%
-4.03
Total Unusual Items Excluding Goodwill
21.72
+15754.74%
0.14
-96.00%
3.42
+184.90%
-4.03
Special Income Charges
-0.03
0.00
+100.00%
-0.34
+90.75%
-3.70
Other Special Charges
0.03
—
—
—
Impairment Of Capital Assets
—
—
—
0.00
Restructuring And Mergern Acquisition
—
0.00
-100.00%
0.34
-90.75%
3.70
Write Off
—
—
—
0.00
Net Income
-113.14
-44.90%
-78.08
-64.41%
-47.49
+29.78%
-67.63
Pretax Income
-113.14
-44.90%
-78.08
-64.41%
-47.49
+29.78%
-67.63
Net Non Operating Interest Income Expense
8.29
+1239.10%
0.62
+2.65%
0.60
+150.21%
0.24
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
8.29
+1239.10%
0.62
+2.65%
0.60
+150.21%
0.24
Interest Expense
—
—
—
0.00
Interest Income Non Operating
8.29
+1239.10%
0.62
+2.65%
0.60
+150.21%
0.24
Interest Income
8.29
+1239.10%
0.62
+2.65%
0.60
+150.21%
0.24
Other Income Expense
21.72
+15754.74%
0.14
-96.00%
3.42
+184.90%
-4.03
Gain On Sale Of Security
21.75
+15775.18%
0.14
-96.36%
3.77
+1214.50%
-0.34
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-113.14
-44.90%
-78.08
-64.41%
-47.49
+29.78%
-67.63
Net Income From Continuing Operation Net Minority Interest
-113.14
-44.90%
-78.08
-64.41%
-47.49
+29.78%
-67.63
Net Income From Continuing And Discontinued Operation
-113.14
-44.90%
-78.08
-64.41%
-47.49
+29.78%
-67.63
Net Income Continuous Operations
-113.14
-44.90%
-78.08
-64.41%
-47.49
+29.78%
-67.63
Normalized Income
-134.86
-72.42%
-78.22
-53.62%
-50.91
+19.94%
-63.60
Net Income Common Stockholders
-113.14
-44.90%
-78.08
-64.41%
-47.49
+29.78%
-67.63
Diluted EPS
-5.59
+19.73%
-6.96
+29.51%
-9.88
+35.00%
-15.20
Basic EPS
-5.59
+19.73%
-6.96
+29.51%
-9.88
+35.00%
-15.20
Basic Average Shares
20.22
+143.72%
8.30
+70.04%
4.88
+10.84%
4.40
Diluted Average Shares
20.22
+143.72%
8.30
+70.04%
4.88
+10.84%
4.40
Diluted NI Availto Com Stockholders
-113.14
-44.90%
-78.08
-64.41%
-47.49
+29.78%
-67.63
Line Item Trend 2024-03-31
Total Assets
302.02
Current Assets
218.54
Cash Cash Equivalents And Short Term Investments
208.99
Cash And Cash Equivalents
208.99
Cash Financial
208.99
Receivables
4.48
Accounts Receivable
4.48
Prepaid Assets
2.89
Other Current Assets
2.18
Total Non Current Assets
83.49
Net PPE
0.55
Gross PPE
1.35
Accumulated Depreciation
-0.81
Machinery Furniture Equipment
0.27
Other Properties
1.09
Goodwill And Other Intangible Assets
82.94
Goodwill
47.48
Other Intangible Assets
35.47
Investments And Advances
—
Total Liabilities Net Minority Interest
10.10
Current Liabilities
10.10
Payables And Accrued Expenses
7.26
Payables
7.26
Accounts Payable
9.80
Other Payable
0.29
Current Debt And Capital Lease Obligation
0.29
Current Capital Lease Obligation
0.29
Total Non Current Liabilities Net Minority Interest
0.00
Tradeand Other Payables Non Current
—
Stockholders Equity
291.93
Common Stock Equity
291.93
Capital Stock
443.88
Common Stock
443.88
Share Issued
20.00
Ordinary Shares Number
20.00
Treasury Shares Number
0.00
Additional Paid In Capital
11.75
Retained Earnings
-226.23
Gains Losses Not Affecting Retained Earnings
-2.29
Other Equity Adjustments
-2.29
Total Equity Gross Minority Interest
291.93
Total Capitalization
291.93
Working Capital
208.44
Invested Capital
291.93
Total Debt
0.29
Capital Lease Obligations
0.29
Net Tangible Assets
208.99
Tangible Book Value
208.99
Other Equity Interest
64.82
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Cash Flow
-101.30
-47.01%
-68.91
-45.28%
-47.43
-4.92%
-45.21
Cash Flow From Continuing Operating Activities
-101.30
-47.01%
-68.91
-45.28%
-47.43
-4.92%
-45.21
Net Income From Continuing Operations
-113.14
-44.90%
-78.08
-64.41%
-47.49
+29.78%
-67.63
Depreciation Amortization Depletion
0.47
+12.03%
0.42
+68.92%
0.25
+49.40%
0.17
Depreciation
0.41
+12.95%
0.36
+69.63%
0.21
+27.38%
0.17
Amortization Cash Flow
0.07
+6.56%
0.06
+64.86%
0.04
0.00
Depreciation And Amortization
0.47
+12.03%
0.42
+68.92%
0.25
+49.40%
0.17
Amortization Of Intangibles
0.07
+6.56%
0.06
+64.86%
0.04
0.00
Other Non Cash Items
0.04
+337.50%
0.01
-97.53%
0.32
-91.18%
3.67
Stock Based Compensation
42.87
+208.72%
13.89
+196.33%
4.69
-74.01%
18.03
Asset Impairment Charge
0.00
-100.00%
0.02
0.00
0.00
Operating Gains Losses
-21.75
-15775.18%
-0.14
+96.60%
-4.03
-1402.59%
0.31
Unrealized Gain Loss On Investment Securities
—
0.00
-100.00%
0.26
+796.55%
0.03
Net Foreign Currency Exchange Gain Loss
-21.75
-15775.18%
-0.14
+96.60%
-4.03
-1402.59%
0.31
Change In Working Capital
-9.79
-94.81%
-5.03
-249.83%
-1.44
-774.65%
0.21
Change In Receivables
-1.41
-29.38%
-1.09
-14.87%
-0.95
-22.64%
-0.77
Changes In Account Receivables
-1.41
-29.38%
-1.09
-14.87%
-0.95
-22.64%
-0.77
Change In Inventory
—
—
—
0.00
Change In Prepaid Assets
-19.27
-1853.85%
-0.99
-113.42%
-0.46
-225.35%
-0.14
Change In Payables And Accrued Expense
11.61
+556.49%
-2.54
-734.41%
0.40
-83.76%
2.47
Change In Other Current Assets
-0.73
-79.41%
-0.41
+4.67%
-0.43
+68.08%
-1.34
Investing Cash Flow
-1.97
-128.40%
6.92
+309.19%
-3.31
-329.74%
-0.77
Cash Flow From Continuing Investing Activities
-1.97
-128.40%
6.92
+309.19%
-3.31
-329.74%
-0.77
Net PPE Purchase And Sale
-1.97
-274.15%
-0.53
-270.04%
-0.14
-35.24%
-0.10
Purchase Of PPE
-1.97
-274.15%
-0.53
-270.04%
-0.14
-35.24%
-0.10
Capital Expenditure
-1.97
-176.90%
-0.71
+78.54%
-3.31
-536.35%
-0.52
Net Investment Purchase And Sale
—
—
0.00
+100.00%
-0.25
Purchase Of Investment
—
—
0.00
+100.00%
-0.25
Net Business Purchase And Sale
0.00
-100.00%
7.63
0.00
0.00
Purchase Of Business
—
—
—
0.00
Net Intangibles Purchase And Sale
—
-0.69
+78.24%
-3.17
-663.13%
-0.41
Purchase Of Intangibles
—
-0.69
+78.24%
-3.17
-663.13%
-0.41
Financing Cash Flow
20.20
-92.06%
254.51
+1776.34%
13.56
-62.09%
35.78
Cash Flow From Continuing Financing Activities
20.20
-92.06%
254.51
+1776.34%
13.56
-62.09%
35.78
Net Issuance Payments Of Debt
-0.29
-94.63%
-0.15
0.00
—
Repayment Of Debt
-0.29
-94.63%
-0.15
0.00
—
Long Term Debt Payments
-0.29
-94.63%
-0.15
0.00
—
Net Long Term Debt Issuance
-0.29
-94.63%
-0.15
0.00
—
Net Common Stock Issuance
20.49
-91.95%
254.60
+1828.50%
13.20
-58.10%
31.51
Proceeds From Stock Option Exercised
0.00
-100.00%
0.06
-84.53%
0.36
-91.52%
4.27
Changes In Cash
-83.07
-143.15%
192.52
+617.86%
-37.18
-264.47%
-10.20
Effect Of Exchange Rate Changes
9.10
+5716.67%
-0.16
-196.43%
0.17
+190.81%
-0.18
Beginning Cash Position
208.99
+1156.49%
16.63
-68.99%
53.64
-16.22%
64.03
End Cash Position
135.02
-35.39%
208.99
+1156.49%
16.63
-68.99%
53.64
Free Cash Flow
-103.27
-48.33%
-69.62
-37.21%
-50.74
-10.96%
-45.73
Common Stock Issuance
20.49
-91.95%
254.60
+1828.50%
13.20
-58.10%
31.51
Issuance Of Capital Stock
20.49
-91.95%
254.60
+1828.50%
13.20
-58.10%
31.51
Sale Of Business
0.00
-100.00%
7.63
0.00
—
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category